The $0.08 EPS beat is entirely non-recurring and masks a deteriorating cash position. Monitor for updates on the strategic alternatives process and any new financing needs, as the $22M cash balance provides limited runway. The stock may see short-term volatility as the market digests the one-time gain versus the underlying cash burn.
Price Chart
Executive Summary
Werewolf Therapeutics reported Q2 2026 net income of $3.7M ($0.08 EPS), a significant swing from a net loss of $18.0M in Q2 2025, driven by a $21.0M collaboration revenue from the sale of its JZP898 program to Jazz Pharmaceuticals. However, cash and cash equivalents dropped sharply to $22.0M from $46.5M at Q1 end, and the company continues to explore strategic alternatives with Piper Sandler, with no defined timeline or guarantee of a transaction. The reported EPS of $0.08 is a beat vs the consensus estimate of $-0.28, but this is entirely due to a non-recurring asset sale, not operational improvement, making the headline beat misleading for ongoing valuation.
Key Financial Metrics
Key Facts
- Q2 2026 net income of $3.7M vs net loss of $18.0M in Q2 2025, driven by $21.0M collaboration revenue from JZP898 sale to Jazz Pharmaceuticals
- Cash and cash equivalents fell to $22.0M from $46.5M at Q1 2026 end; cash runway expected into Q2 2027
- EPS of $0.08 beat consensus estimate of $-0.28, but the beat is entirely non-recurring and not operational
- Company continues to explore strategic alternatives with Piper Sandler; no timeline or guarantee of a transaction
- Research and development expenses decreased to $6.2M from $13.1M in Q2 2025; G&A increased to $7.7M from $4.4M
Financial Impact
$21.0M collaboration revenue from JZP898 sale; cash burn of ~$24.5M in Q2 2026
Risk Factors
- Cash runway only into Q2 2027; potential need for dilutive financing if no strategic transaction materializes
- Strategic alternatives process may not result in any transaction, creating uncertainty
- Non-recurring revenue masks ongoing operational losses; R&D and G&A expenses continue to consume cash
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3336715 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-4/A | $0.9806 | awaiting T+5 | — | $0.9810 (−0.04%) |
Sep 22, 2026 4w ago | S-4 | $0.9894 $0.9223 | ▲ +6.78% | ▲ +6.11% | $0.9810 (+0.85%) |
Sep 21, 2026 5w ago | SC 13G | $0.9800 $0.9300 | ▼ −5.10% | ▼ −4.08% | $0.9810 (+0.10%) |
Aug 21, 2026 9w ago | 425 | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $0.9810 (+12.24%) |
Aug 21, 2026 9w ago | 8-K | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $0.9810 (+12.24%) |
Aug 21, 2026 9w ago | Press Release | $0.8740 $0.9433 | ▼ −7.93% | ▼ −7.46% | $0.9810 (−12.24%) |
Jul 31, 2026 12w ago | 8-K | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $0.9810 (+177.82%) |
Jul 31, 2026 12w ago | Press Release | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $0.9810 (+177.82%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $0.9810 (−172.58%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $0.9810 (−172.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers